MedTrace Logo

AGN-242428 in the Treatment of Plaque Psoriasis

NCT03339999 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-04-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of AGN-242428 in adult participants with moderate to severe plaque-type psoriasis.

Conditions

Interventions

DRUG

AGN-242428

AGN-242428 administered as an oral capsule(s) once daily.

DRUG

Placebo

Placebo administered as an oral capsule(s) once daily.

Sponsors & Collaborators

  • Vitae Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Christy Harutunian · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-15
Primary Completion
2018-03-22
Completion
2018-04-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03339999 on ClinicalTrials.gov